Sumitomo Pharma Co., Ltd.

4506

JP3495000006

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-16 am EDT			5-day change	1st Jan Change
355 ^JPY	-5.59%		-5.84%	-23.82%

May. 09	Sumitomo Pharma Co., Ltd. agreed to acquire MELTz Business of MELTIN MMI Co., Ltd.	CI
May. 07	Profit-Taking, China Outlooks Churn Asian Stock Markets	MT

Dainippon Sumitomo Pharma Co., Ltd. Announces Changes in Executive Officer Posts, Effective June 1, 2014

May 07, 2014

Dainippon Sumitomo Pharma Co., Ltd. announced the changes in the posts assumed by Executive Officer Masaru Ishidahara from Corporate Communications; Personnel; General Affairs; Procurement; Corporate Service Center to Corporate Communications; Personnel; General Affairs; Procurement; Corporate Service Center; Osaka Administration, with effect from June 1, 2014.

Latest news about Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd. agreed to acquire MELTz Business of MELTIN MMI Co., Ltd.	May. 08	CI
Profit-Taking, China Outlooks Churn Asian Stock Markets	May. 07	MT
Fed Outlook, Earnings Season Roil Asian Stock Markets	May. 02	MT
Sumitomo Pharma Sees Impairment Losses and Restructuring Expenses in Fiscal 2024	May. 02	MT
Sumitomo Pharma Expects Substantial Valuation Loss on Subsidiary Shares; Assures No Impact on Consolidated Profit	May. 02	MT
Lull in Geopolitical Tensions Lifts Asian Stock Markets	Apr. 22	MT
Jefferies Adjusts Sumitomo Pharma’s Price Target to 420 Yen From 520 Yen, Keeps at Hold	Apr. 17	MT
Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise	Apr. 02	MT
Roivant's anti-inflammatory drug succeeds in mid-stage study	Apr. 02	RE
Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical	Mar. 17	MT
Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from S&P Japan 500	Mar. 17	CI
Sumitomo Pharma Enters into an Agreement to Amend the Worldwide Collaboration and License Agreement for Four Psychiatry and Neurology Compounds Including Ulotaront with Otsuka	Mar. 15	CI
US Inflation Report Lifts Asian Stock Markets	Mar. 01	MT
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses	Feb. 16	MT
Japan's Nikkei slips after Fed chair signals delay in rate cut	Jan. 31	RE
Transcript : Sumitomo Pharma Co., Ltd., Q3 2024 Earnings Call, Jan 31, 2024	Jan. 31
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	Jan. 31	CI
Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024	Jan. 31	CI
Fed, China Property Outlooks Roil Asian Stock Markets	Jan. 30	MT
Japan's Nikkei rounds off 2023 with biggest yearly gain in a decade	Dec. 29	RE
Interest Rates, China Housing Measures Lift Asian Stock Markets	Dec. 15	MT
China Real Estate, FX Roil Asian Stock Markets	Nov. 29	MT
Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®	Nov. 02	CI
European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis	Nov. 02	CI
Japanese Shares End Higher on Tuesday After BOJ Kept Rate Unchanged; Shares of Nippon Electric Glass Jump Over 10%	23-10-31	MT

Chart Sumitomo Pharma Co., Ltd.

Duration

Period

More charts

Company Profile

Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceuticals (92.9%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems disorders and allergies treatment; - other (7.1%): veterinary drugs, food additives, industrial chemical products, etc. Net sales are distributed geographically as follows: Japan (39.8%), the United States (50.4%), North America (0.9%) and other (8.9%).

Sector

Pharmaceuticals

Calendar

2024-07-28 - Q1 2024 Earnings Release (Projected)

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Sumitomo Pharma Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

376 JPY

Average target price

333.8 JPY

Spread / Average Target

-11.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SUMITOMO PHARMA CO., LTD.	-23.82%	965M
ELI LILLY AND COMPANY	+33.85%	709B
NOVO NORDISK A/S	+30.60%	595B
JOHNSON & JOHNSON	-2.42%	367B
MERCK & CO., INC.	+20.41%	334B
ABBVIE INC.	+5.09%	289B
ASTRAZENECA PLC	+14.11%	239B
NOVARTIS AG	+9.01%	211B
ROCHE HOLDING AG	-3.80%	203B
AMGEN INC.	+8.30%	171B

Other Pharmaceuticals

Sumitomo Pharma Co., Ltd.

Equities

4506

JP3495000006

Pharmaceuticals

Dainippon Sumitomo Pharma Co., Ltd. Announces Changes in Executive Officer Posts, Effective June 1, 2014

EPS Revisions